A novel mechanism for isoprenaline-stimulated proliferation of rat parotid acinar cells involving the epidermal growth factor receptor and cell surface galactosyltransferase.
Chronic injections of epidermal growth factor (EGF) or the beta-adrenergic receptor agonist isoprenaline resulted in rat parotid gland hypertrophy and hyperplasia. Introduction of a polyclonal antibody to EGF or the EGF-receptor (EGF-R) caused a specific retardation of acinar cell proliferation when injected along with the growth factor. Meanwhile, only the antibody to EGF-R caused a dose-dependent retardation of proliferation on co-administration with isoprenaline both in vivo and in vitro. The antibody injected alone had no effect on cell growth. When cells were incubated in the presence of EGF, plasma membranes from isoprenaline-treated and control animals showed phosphorylation of the EGF-R tyrosine moieties and transient increases in membrane-associated phospholipase C gamma. Isoprenaline did not stimulate phosphorylation of the EGF-R in isolated plasma membranes. However, activation of the phosphotyrosine-signalling pathway could be duplicated by incubating isoprenaline-treated acinar cells, but not control cells, with bovine galactosyltransferase. Immunopurified EGF-R demonstrated variations in reactivity with two different lectins after treatment of the cells with the beta-agonist as well as increased galactosyltransferase substrate capacity in vitro. In addition, incubation of intact acinar cells and isolated plasma-membrane fractions from isoprenaline-treated rats with UDP-[14C]galactose resulted in an increased incorporation of label into the EGF-R. The results suggest that the carbohydrate moiety of the EGF-R has been altered in isoprenaline-treated animals allowing galactosyltransferase now to recognize this receptor. This interaction may in part mediate proliferation of parotid acinar cells. Indeed, we have previously shown that an antibody to galactosyltransferase is capable of blocking isoprenaline-mediated acinar cell proliferation in vivo [Humphreys-Beher, Schneyer, Kidd & Marchase (1987) J. Biol. Chem. 262, 11706-11713].
Purushotham
K R
KR
Department of Oral Biology, University of Florida, Gainesville 32610.
Dunn
W A
WA
Schneyer
C A
CA
Humphreys-Beher
M G
MG
D000818:Animals; D000906:Antibodies; D000911:Antibodies, Monoclonal; D002455:Cell Division / Q000187:drug effects; D002460:Cell Line; D002462:Cell Membrane / Q000201:enzymology; D004261:DNA Replication / Q000187:drug effects; D004591:Electrophoresis, Polyacrylamide Gel; D004815:Epidermal Growth Factor / Q000276:immunology / Q000494:pharmacology*; D066246:ErbB Receptors / Q000187:drug effects / Q000302:isolation & purification / Q000502:physiology*; D005260:Female; D005700:Galactosyltransferases / Q000378:metabolism*; D006801:Humans; D006965:Hyperplasia; D006984:Hypertrophy; D015151:Immunoblotting; D007545:Isoproterenol / Q000494:pharmacology*; D008562:Membrane Glycoproteins / Q000302:isolation & purification / Q000378:metabolism*; D008954:Models, Biological; D008970:Molecular Weight; D010306:Parotid Gland / Q000166:cytology* / Q000187:drug effects / Q000473:pathology / Q000502:physiology; D051381:Rats; D011919:Rats, Inbred Strains; D014531:Uridine Diphosphate Galactose / Q000378:metabolism
D000906:Antibodies; D000911:Antibodies, Monoclonal; D008562:Membrane Glycoproteins; D014531:Uridine Diphosphate Galactose; D004815:Epidermal Growth Factor; D005700:Galactosyltransferases; D066246:ErbB Receptors; D007545:Isoproterenol